100460-87-5

Basic information

• Product Name: 2H-Benzimidazol-2-one,1-[(4-fluorophenyl)methyl]-1,3-dihydro-
• CAS NO: 100460-87-5
• Molecular Formula: C14H11 F N2 O
• Molecular Weight: 242.253
• Mol File: 100460-87-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2H-Benzimidazol-2-one,1-[(4-fluorophenyl)methyl]-1,3-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Benzimidazol-2-one,1-[(4-fluorophenyl)methyl]-1,3-dihydro-(100460-87-5)
• EPA Substance Registry System: 2H-Benzimidazol-2-one,1-[(4-fluorophenyl)methyl]-1,3-dihydro-(100460-87-5)

Safety Data

• Hazardous Substances Data: 100460-87-5(Hazardous Substances Data)

Usage

General Description

The compound "2H-Benzimidazol-2-one,1-[(4-fluorophenyl)methyl]-1,3-dihydro-" is a chemical with the molecular formula C15H13FN2O. It is a derivative of benzimidazole and contains a 1,3-dihydro-2H-benzimidazol-2-one core. The compound features a substituted fluoro-phenyl group, which is attached to the 1-position of the benzimidazol-2-one ring. This chemical structure suggests potential applications in pharmaceutical research as a possible drug candidate. Further studies on this compound may reveal its pharmacological properties and potential therapeutic uses.

Upstream product

• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 84946-20-3 2-chloro-1-(4-fluorobenzyl)-1H-benzimidazole 
• 1042308-43-9 C₁₄H₁₂FIN₂O 
• 88-74-4 2-nitro-aniline 
• 459-46-1 4-Fluorobenzyl bromide 
• 7191-70-0 N-(4''-fluorobenzyl)-1,2-phenylenediamine 
• 57-13-6 urea 
• 1048344-51-9 1-(2-bromophenyl)-1-(4-fluorobenzyl)urea 
• 100460-81-9 (4-Fluoro-benzyl)-(2-nitro-phenyl)-carbamic acid ethyl ester 
• 100460-79-5 N-(4''-fluorobenzyl)-2-nitroaniline 
• 615-16-7 1H-benzimidazol-2-ol 
• 352-11-4 1-chloromethyl-4-fluorobenzene 

Downstream Products

• 75970-64-8 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 
• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 68844-77-9 astemizole 
• 84946-20-3 2-chloro-1-(4-fluorobenzyl)-1H-benzimidazole 

Relevant articles and documents

Properly tuned first fluoride-catalyzed TGME-mediated amination process for chloroimidazoles: Inexpensive technology for antihistaminic norastemizole

Fluoride-catalyzed amination process of chloroimidazole 1 proved to be a practical and inexpensive procedure for the preparation of the antihistaminic, norastemizole.

Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a] benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi

A high-throughput (HTS) and high-content screening (HCS) campaign of a commercial library identified 2,3-dihydroimidazo[1,2-a]benzimidazole analogues as a novel class of anti-parasitic agents. A series of synthetic derivatives were evaluated for their in vitro anti-leishmanial and anti-trypanosomal activities against Leishmania donovani and Trypanosoma cruzi, which have been known as the causative parasites for visceral leishmaniasis and Chagas disease, respectively. In the case of Leishmania, the compounds were tested in both intracellular amastigote and extracellular promastigote assays. Compounds 4 and 24 showed promising anti-leishmanial activity against intracellular L. donovani (3.05 and 5.29 μM, respectively) and anti-trypanosomal activity against T. cruzi (1.10 and 2.10 μM, respectively) without serious cytotoxicity toward THP-1 and U2OS cell lines.

Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified.

Copper-catalyzed intramolecular N-arylation of ureas in water: a novel entry to benzoimidazolones

The copper-catalyzed intramolecular N-arylation of 2-bromoarylureas performed in water leading to the benzo[d]imidazolone framework is reported. The scope of the methodology presented herein proved to?be broad and afforded a significant number of benzoimidazolones in good to excellent yields. The reported protocol is based on the use of CuI and TMEDA acting both as the ligand and as the base in a water solution, which allows for the easy separation of the catalyst containing aqueous phase from the products by simple extraction. Additionally, the N- versus O-arylation competitive processes are also discussed.